Apotex To Retain About $300 Million From Its At-Risk Launch of Generic Plavix
This article was originally published in The Pink Sheet Daily
Executive Summary
A judge sets damages at 50% of Apotex's net sales of generic clopidogrel plus prejudgment interest of $107.9 million.